Analysts Offer Predictions for MiMedx Group FY2024 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG) – Stock analysts at Northland Capmk boosted their FY2024 earnings per share (EPS) estimates for shares of MiMedx Group in a research report issued on Thursday, October 31st. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings of $0.28 per share for the year, up from their previous forecast of $0.23. The consensus estimate for MiMedx Group’s current full-year earnings is $0.26 per share. Northland Capmk also issued estimates for MiMedx Group’s Q4 2024 earnings at $0.07 EPS.

A number of other equities analysts have also recently weighed in on the stock. StockNews.com upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a research report on Thursday, August 1st. Finally, Craig Hallum dropped their price target on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Performance

Shares of MDXG stock opened at $7.13 on Monday. The company has a market capitalization of $1.05 billion, a P/E ratio of 12.96 and a beta of 1.94. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $9.27. The business’s 50 day moving average is $6.07 and its two-hundred day moving average is $6.68. The company has a current ratio of 4.10, a quick ratio of 3.22 and a debt-to-equity ratio of 0.10.

Institutional Trading of MiMedx Group

Several large investors have recently added to or reduced their stakes in the stock. Isthmus Partners LLC boosted its position in shares of MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after acquiring an additional 91,714 shares during the last quarter. Headlands Technologies LLC acquired a new position in MiMedx Group in the 1st quarter valued at about $27,000. Blue Trust Inc. purchased a new stake in shares of MiMedx Group in the 3rd quarter valued at approximately $30,000. Point72 Asset Management L.P. purchased a new stake in shares of MiMedx Group in the 2nd quarter valued at approximately $40,000. Finally, Quest Partners LLC acquired a new stake in shares of MiMedx Group during the 2nd quarter worth approximately $81,000. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.